Literature DB >> 8255365

Monoamine oxidase inhibitors and the cheese effect.

M C Anderson1, F Hasan, J M McCrodden, K F Tipton.   

Abstract

The behavior of inhibitors of monoamine oxidase-A (MAO-A) is considered in terms of the possibility of having an effective antidepressant that does not give rise to hypertensive interactions with dietary tyramine. Studies with punch-biopsy samples of human intestine and rat intestinal samples show MAO-A to be the predominant form of the enzyme in both species. Transport studies with everted rat intestinal preparations indicate that tyramine is extensively metabolized during transport through the intestine. Selective inhibition of MAO-A by clorgyline results in a large increase in the amount of unchanged tyramine transported, whereas selective inhibition of MAO-B with L-deprenyl (selegiline) has no significant effect. The behavior of reversible MAO-A inhibitors can significantly reduce, but not entirely eliminate, these effects on the intestinal metabolism of tyramine, but only if the inhibition is competitive in nature.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8255365     DOI: 10.1007/bf00978365

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  21 in total

1.  The inhibition of monoamine oxidase by brofaromine.

Authors:  M C Anderson; P C Waldmeier; K F Tipton
Journal:  Biochem Pharmacol       Date:  1991-06-15       Impact factor: 5.858

Review 2.  From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors.

Authors:  M Da Prada; R Kettler; H H Keller; A M Cesura; J G Richards; J Saura Marti; D Muggli-Maniglio; P C Wyss; E Kyburz; R Imhof
Journal:  J Neural Transm Suppl       Date:  1990

Review 3.  Neuronal monoamine oxidase: specific enzyme types and their rates of formation.

Authors:  N H Neff; C Goridis
Journal:  Adv Biochem Psychopharmacol       Date:  1972

4.  Cumulative effects of irreversible MAO inhibitors in vivo.

Authors:  A E Felner; P C Waldmeier
Journal:  Biochem Pharmacol       Date:  1979-04-01       Impact factor: 5.858

5.  The labeling in vivo of monoamine oxidase by 14 C-pargyline: a tool for studying the synthesis of the enzyme.

Authors:  V G Erwin; R A Deitrich
Journal:  Mol Pharmacol       Date:  1971-03       Impact factor: 4.436

6.  Determination of monoamine oxidase.

Authors:  K F Tipton
Journal:  Methods Find Exp Clin Pharmacol       Date:  1985-07

7.  Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[11C]deprenyl.

Authors:  C D Arnett; J S Fowler; R R MacGregor; D J Schlyer; A P Wolf; B Långström; C Halldin
Journal:  J Neurochem       Date:  1987-08       Impact factor: 5.372

8.  The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

Authors:  J W Tetrud; J W Langston
Journal:  Science       Date:  1989-08-04       Impact factor: 47.728

9.  The monoamine oxidase inhibiting properties of CGP 11305 A.

Authors:  P C Waldmeier; A E Felner; K F Tipton
Journal:  Eur J Pharmacol       Date:  1983-10-14       Impact factor: 4.432

10.  Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat.

Authors:  M S Benedetti; T Boucher; A Carlsson; C J Fowler
Journal:  Biochem Pharmacol       Date:  1983-01-01       Impact factor: 5.858

View more
  23 in total

1.  Purification and characterization of membrane-bound semicarbazide-sensitive amine oxidase (SSAO) from bovine lung.

Authors:  J M Lizcano; K F Tipton; M Unzeta
Journal:  Biochem J       Date:  1998-04-01       Impact factor: 3.857

2.  Cerebral MAO Activity Is Not Altered by a Novel Herbal Antidepressant Treatment.

Authors:  Ravid Doron; Ziv Versano; Or Burstein; Motty Franko; Alon Shamir; Roni Toledano; Assaf Handelsman; Moshe Rehavi
Journal:  J Mol Neurosci       Date:  2019-07-09       Impact factor: 3.444

Review 3.  90 years of monoamine oxidase: some progress and some confusion.

Authors:  Keith F Tipton
Journal:  J Neural Transm (Vienna)       Date:  2018-04-10       Impact factor: 3.575

Review 4.  Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence.

Authors:  Marco Bortolato; Jean C Shih
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

5.  Synthesis, molecular modeling, and in vitro screening of monoamine oxidase inhibitory activities of some novel hydrazone derivatives.

Authors:  Umut Salgin-Gökşen; Nesrin Gökhan-Kelekçi; Samiye Yabanoglu-Çiftci; Kemal Yelekçi; Gülberk Uçar
Journal:  J Neural Transm (Vienna)       Date:  2013-01-18       Impact factor: 3.575

Review 6.  The molecular basis of familial dysautonomia: overview, new discoveries and implications for directed therapies.

Authors:  Berish Y Rubin; Sylvia L Anderson
Journal:  Neuromolecular Med       Date:  2007-11-06       Impact factor: 3.843

Review 7.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

8.  Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157.

Authors:  Joanna S Fowler; Jean Logan; Albert J Azzaro; Robert M Fielding; Wei Zhu; Amy K Poshusta; Daniel Burch; Barry Brand; James Free; Mahnaz Asgharnejad; Gene-Jack Wang; Frank Telang; Barbara Hubbard; Millard Jayne; Payton King; Pauline Carter; Scott Carter; Youwen Xu; Colleen Shea; Lisa Muench; David Alexoff; Elena Shumay; Michael Schueller; Donald Warner; Karen Apelskog-Torres
Journal:  Neuropsychopharmacology       Date:  2009-11-04       Impact factor: 7.853

9.  Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.

Authors:  Pablo Duarte; Antonio Cuadrado; Rafael León
Journal:  Handb Exp Pharmacol       Date:  2021

10.  Evaluation of selective human MAO inhibitory activities of some novel pyrazoline derivatives.

Authors:  Umut Salgin-Gökşen; Samiye Yabanoğlu-Çiftçi; Ayşe Ercan; Kemal Yelekçi; Gülberk Uçar; Nesrin Gökhan-Kelekçi
Journal:  J Neural Transm (Vienna)       Date:  2013-01-30       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.